newsfilter
← Latest News
GlobeNewswire·

Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results

Teva-discovered TEV-’408 targets IL-15, a key driver of vitiligo biology TEV-’408 showed improvement in skin pigmentation and was well-tolerated with no safety signals observed to dateNearly 75% of patients reported